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Benign prostatic hyperplasia (BPH) is one of the most common chronic diseases affecting men and it
increases in both incidence and prevalence with age. This work presents a simple, sensitive and fast gen-
eric high performance thin layer chromatographic (HPTLC) method for the simultaneous determination
of ﬁve drugs prescribed for the treatment of BPH. These drugs include the a1-adrenergic blockers; alfuz-
osin hydrochloride (ALF), terazosin hydrochloride (TER), prazosin hydrochloride (PRZ) and doxazosin
mesylate (DOX) in addition to the 5a-reductase inhibitor; ﬁnasteride (FIN). The cited drugs were sepa-
rated on TLC-silica plates using a mobile phase composed of methylene chloride:n-hexane:methanol
(8.8:0.3:0.9, by volume). Densitometric analysis was carried out at 254 nm for the a-blockers while
FIN was measured at 220 nm. The ﬁve drugs were detected at Rf values of 0.26, 0.36, 0.45, 0.59 and
0.69 for ALF, TER, PRZ, DOX and FIN, respectively. The developed method was validated according to
the International Conference on Harmonization (ICH) guidelines regarding; linearity, ranges, accuracy,
precision, selectivity, robustness and limits of detection and quantiﬁcation. The proposed method
showed good linearity (r > 0.9990) in the ranges; 30–350, 30–350, 20–200, 30–350, 200–2000 ng/spot
for the cited drugs, respectively. The applicability of the proposed method was veriﬁed through the anal-
ysis of laboratory-prepared mixtures and percentage recoveries between 98.27% and 101.97% were
obtained. Commercial tablets were also analyzed by the developed methodology with no interference
detected from the co-formulated excipients. The high sensitivity, simplicity and selectivity of the pro-
posed method suggest its applicability for routine quality-control analysis purposes of any of the titled
drugs in their pharmaceutical preparations.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Benign prostatic hyperplasia (BPH) is a common disorder of the
male urogenital tract and it is the main cause of lower urinary tract
symptoms (LUTS) in older men. It affects almost 50–90% of the men
aging from 50 to 85 years [1]. Compared to surgery, pharmacologi-
cal intervention results in signiﬁcant improvement of the symp-
toms with fewer, less serious and reversible side effects. Two
main pharmacological classes of drugs are available; the selective
a1-adrenoreceptor blockers and the 5a-reductase inhibitors. The
ﬁrst acts by the selective blockade of the a1-adrenoreceptors that
are widely distributed in the prostatic tissues, thus inhibiting thesympathetic stimulation of the prostatic smooth muscles and
relieving the urinary obstruction [1]. The alternative treatment
strategy is the 5a-reductase inhibitors that exert their action by
interrupting the conversion of testosterone into 5a-dihydrotestos-
terone and therefore reducing the prostate volume [2]. In addition
to monotherapy, several studies have proven the beneﬁcial use of
these drugs in combination for treating men at higher risk of BPH
progression [1–3]. The a1-adrenoreceptor blocker family includes,
but not exclusive to; alfuzosin hydrochloride (ALF), doxazosin mes-
ylate (DOX), prazosin hydrochloride (PRZ) and terazosin hydrochlo-
ride (TER) [1,3]. All four members share a similar nucleus, namely;
the 4-amino-6,7-dimethoxyquinazoline (Fig. 1). On the other hand,
ﬁnasteride (FIN) is a 5a-reductase inhibitor, and it is chemically
known as N-tert-butyl-3-oxo-4-aza-5a-androst-1-ene-17b-car-
boxamide (Fig. 1) [3].
Fig. 1. Chemical structures of ALF, TER, PRZ, DOX and FIN.
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the determination of these ﬁve drugs in different matrices. A cou-
ple of review articles were published where they provided infor-
mation about the various analytical methods available for these
drugs [4,5]. In this work, special emphasis will be given to analyt-
ical reports involving the use of HPTLC. Such technique was used
for the quantiﬁcation of ALF in plasma [6] as well as in tablets
either alone [7] or in the presence of its forced degradation prod-
ucts [8]. DOX was also assayed in tablets using HPTLC [9,10]. In
addition, HPTLC methods were reported for the simultaneous
determination of the binary mixtures; ALF/solifenacin [11], DOX/
celecoxib [12] and FIN/tamsulosin [13]. Furthermore, TLC methods
were applied for detection of 29 different pharmaceutical com-
pounds including DOX, PRZ and TER in adulterated herbal remedies
[14].
On the other hand, several reports investigated the simulta-
neous quantiﬁcation of either of the selected drugs with one
another or with other pharmacologically related compounds using
several chromatographic methods. The use of a monolithic weak
cation-exchange column was described in the HPLC concomitant
determination of ALF, DOX, PRZ and TER in human plasma [15].
DOX, PRZ and TER were also simultaneously assayed using a stabil-
ity-indicating HPLC-UVmethod [16]. In addition, PRZ and TER were
concurrently determined via HPLC methods in tablets [17] and in
biological ﬂuids [18]. Moreover, HPLC with UV detection methods
were presented for the speciﬁc determination of DOX, PRZ and TER
in presence of their degradation products [19]. On the other hand,
FIN was simultaneously determined with tamsulosin in combined
dosage forms using several HPLC methods [13,20,21]. Finally, ﬂowinjection analysis with ﬂuorescence detection method was recently
reported for determination of the four a1-blockers in pharmaceuti-
cal formulations [22].
To the best of our knowledge, we could not ﬁnd any articles in
the literature describing the simultaneous determination of the
ﬁve selected drugs by any analytical methodology. Moreover, no
reports could be found for the simultaneous determination of the
four structurally related a1-blockers using HPTLC. This encouraged
us to investigate the development of a generic, simple and selective
HPTLC procedure applicable for the routine quality control analysis
of any of the designated drugs in their pure or tablets dosage
forms.2. Experimental
2.1. Materials and reagents
ALF was kindly provided by Amriya Pharmaceutical Industries
(Alexandria, Egypt), while, DOX was a gratuity from the Egyptian
International Pharmaceutical Industries Co., EIPICO (10th of Rama-
dan City, Egypt). PRZ and TER were supplied by Pﬁzer Egypt S.A.E.
(Cairo, Egypt) and European Egyptian Pharmaceutical Industries
(Alexandria, Egypt), respectively. FIN was generously donated by
Adwia Co. S.A.E. (10th of Ramadan City, Egypt). HPLC grade meth-
anol was purchased from Lab-Scan Analytical Sciences (Gliwice,
Poland). Methylene chloride (CDH, India), HPLC grade n-hexane
(Carlo Erba, France), absolute ethanol (BDH Laboratory Suppliers,
Poole, England) and ethyl acetate (Chemajet Chemical Company,
T.S. Belal et al. / Analytical Chemistry Research 1 (2014) 23–31 25Egypt) were used. All other chemicals and solvents used were of
analytical grade.
Xatral SR tablets labeled to contain ALF 5 mg (B.N. 517901 [B])
are manufactured by Amriya Pharmaceutical Industries (Alexan-
dria, Egypt) under license of Laboratoires Synthelabo, Synthelabo
groupe, Le Plessis Robinson, France. Cardura tablets (B.N. 2202)
labeled to contain DOX 4 mg and Minipress tablets (B.N. 1762)
containing PRZ 2 mg are manufactured by Pﬁzer Egypt S.A.E.
(Cairo, Egypt) under authority of Pﬁzer Inc, USA. Itrin tablets
(B.N. 06939/3J) labeled to contain TER 5 mg are manufactured by
Kahira Pharmaceuticals & Chemical Industries Company (Cairo,
Egypt) under license from Abbott laboratories (Abbott Park, IL,
USA). Proscar tablets labeled to contain FIN 5 mg (B.N. 310510)
are manufactured by MSD (Merck Sharp & Dome, Whitehouse Sta-
tion, NJ, USA).
2.2. Instrumentation
The precoated TLC silica gel aluminum plates 60F254
(20  15 cm, 200 lm thickness) used in the study were purchased
from Fluka (Buchs, Switzerland). Samples were spotted on plates in
the form of 5 mm-wide bands using a Camag microliter syringe
under nitrogen stream with the aid of Camag Linomat IV sample
applicator (Switzerland). Sample volume was ﬁxed at 5 lL and
applied at a rate of 0.15 lL/s and at a distance of 4 mm apart. Fol-
lowing sample application, plate development was achieved in the
linear ascending mode using 20 mL of the mobile phase consisting
of methylene chloride, n-hexane and methanol (8.8:0.3:0.9, by vol-
ume). A Camag twin trough glass chamber (20  20 cm) pre-satu-
rated with the mobile phase for 15 min at room temperature was
used for development. The length of the chromatogram run was
135 ± 2 mm. Subsequent to development, the plates were air dried
and scanned densitometrically in the absorbance mode at 254 nm
for ALF, TER, PRZ and DOX determination and at 220 nm for the
determination of FIN using Camag TLC scanner III operated by CATS
software (V 3.15). The slit dimensions were adjusted at
4  0.45 mm, and a scanning speed of 20 mm/s was employed.
The deuterium lamp was used as the radiation source.
2.3. General procedure
Methanolic stock solutions of ALF, TER and DOXwere separately
prepared at a concentration of 250 lg/mL. PRZ 200 lg/mL and FIN
2000 lg/mL stock solutions were also prepared in methnol. Stock
solutions were kept refrigerated at 4 C and protected from light.Table 1
Regression and statistical parameters for the determination of ALF, DOX, PRZ, TER and FIN
Parameter ALF TER
Wavelength (nm) 254 254
Concentration range (ng/spot) 30–350 30–350
Intercept (a) 28.79 60.39
Saa 33.86 39.24
Slope (b) 14.23 13.24
Sbb 0.24 0.18
RSD% of the slope (Sb%) 1.69 1.36
Correlation coefﬁcient (r) 0.9994 0.9996
Sy/xc 47.45 55.74
Fd 3575 5453
Signiﬁcance F 4.7  107 2.0  107
LODe (ng/spot) 7.85 9.78
LOQf (ng/spot) 23.80 29.64
a Standard deviation of the intercept.
b Standard deviation of the slope.
c Standard deviation of residuals.
d Variance ratio, equals the mean of squares due to regression divided by the mean o
e Limit of detection.
f Limit of quantiﬁcation.For the construction of calibration curves, serial portions of the
previous stock solutions were separately transferred into 5 sets of
10 mL volumetric ﬂasks to produce working standard solutions of
concentrations 6–70, 6–70, 4–40, 6–70 and 40–400 lg/mL for
ALF, TER, PRZ, DOX and FIN, respectively. All ﬂasks were completed
to volume with methanol. From these working standard solutions,
5-lL portions were spotted as bands on HPTLC plates to obtain
ﬁnal concentrations of 30–350, 30–350, 20–200, 30–350 and
200–2000 ng/spot for ALF, TER, PRZ, DOX and FIN, respectively.
Sample spotting as well as plate development and scanning were
performed as mentioned under Instrumentation. For each drug,
the obtained peak areas were correlated to the corresponding con-
centrations and the regression equation was developed.
2.4. Application of the proposed method
2.4.1. Analysis of laboratory prepared mixtures
Aliquots from the stock solutions were transferred into 10 mL
volumetric ﬂasks to produce synthetic mixtures containing the 5
drugs at different concentrations, and the ﬂasks were completed
to volume with methanol. From these mixture solutions, 5-lL por-
tions were spotted on HPTLC plates to obtain ﬁnal concentrations
within the speciﬁed linearity ranges (Table 1). Spot application,
plate development and scanning were performed as mentioned
under Instrumentation. The peak area of each drug in every mix-
ture was recorded and the recovered concentration was calculated
from the corresponding regression equation.
2.4.2. Analysis of tablets
For the analysis of each drug in its single component pharma-
ceutical preparation, twenty tablets were accurately weighed,
ﬁnely powdered and thoroughly mixed. For every preparation, a
quantity of the powdered tablets was precisely weighed so as to
contain 12.5 mg of either ALF, TER or DOX, 10 mg of PRZ or
50 mg of FIN. The measured weight was extracted with 25 mL
methanol with the aid of vortex mixing for 10 min. The obtained
extract was ﬁltered into a 50 mL volumetric ﬂask and the residue
was washed with 2  10 mL portions of methanol. The washings
were combined with the corresponding extract solution and the
volume was completed to mark with methanol. The produced tab-
let-extract solutions were labeled to contain 250 lg/mL ALF,
250 lg/mL DOX, 250 lg/mL TER, 200 lg/mL PRZ or 1000 lg/mL
FIN. Accurate volumes from the aforementioned extract solutions
were separately transferred into 10 mL volumetric ﬂasks to pre-
pare working sample solutions and the ﬂasks were completed tousing the proposed HPTLC method.
PRZ DOX FIN
254 254 220
20–200 30–350 200–2000
29.07 96.74 45.84
40.07 45.32 67.56
28.63 15.64 3.68
0.33 0.23 0.06
1.15 1.47 1.63
0.9997 0.9996 0.9995
55.37 70.37 82.71
7489 4681 4228
1.1  107 2.7  107 3.4  107
4.62 9.56 60.58
14.00 28.98 183.59
f squares about regression (due to residuals).
Fig. 2. Mixture of ALF 100 ng/spot, TER 100 ng/spot, PRZ 200 ng/spot, DOX 200 ng/spot and FIN 500 ng/spot at (a) 254 nm and (b) 220 nm.
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portions were spotted on HPTLC plates to obtain ﬁnal concentra-
tions within the speciﬁed linearity ranges (Table 1). Samples were
analyzed as mentioned under Instrumentation and General Proce-
dure and the found concentrations were calculated from similarly
prepared external standard solutions. For standard addition assay,
sample solutions were spiked with aliquots of standard solutions
of the corresponding drugs to obtain total concentrations within
the previously speciﬁed ranges then treated as under General Pro-
cedure. Recovered concentrations were calculated by comparing
the analyte response with the increment response attained after
addition of the standard.3. Results and discussion
3.1. Optimization of the mobile phase and the detection wavelength
Preliminary trials were directed towards the separation of all
ﬁve drugs on 10 cm TLC plates. Mobile phases composed of: [ethylacetate and ethanol], [ethyl acetate and methanol], [methylene
chloride and ethanol], [methylene chloride and methanol], [meth-
ylene chloride and isopropanol], [toluene and ethanol] or [toluene
and methanol], in different ratios, failed to resolve the investigated
drugs. Although that those containing ethyl acetate provided
slightly better resolutions, still, in all cases, the co-elution of ALF
with TER and/or DOX with FIN was observed. Further increase in
solvent polarity resulted in the co-elution of FIN with the solvent
front. Therefore, it was clear that the use of 15-cm TLC plates for
development is inevitable. Initially, mobile phases composed of
different ratios of ethyl acetate with either ethanol or methanol
were tried and the following elution order was observed; ALF,
TER, PRZ, DOX and ﬁnally FIN. The ethyl acetate/methanol mixture
was slightly better in terms of resolution, however, spots were
broad and diffuse and those of DOX and FIN overlap. As the a-
blockers bear a basic center, ammonia seemed as an appropriate
additive to this mobile phase in order to overcome spot tailing as
well as to enhance peak shape and resolution. In general, the [ethyl
acetate:methanol:ammonia] system resulted in reversing the
order of elution to become as follows: TER, ALF, PRZ, FIN and ﬁnally
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system was tried and all resulted in the constant co-elution of FIN
with either PRZ or DOX as well as relatively large Rf values. In fact,
the addition of ammonia had a negative impact of compounds’ res-
olution with only slight improvement in peak shape, therefore, its
use in the ethyl acetate: methanol system was excluded. After-
wards, trials were directed towards enhancing the resolution of
the aforementioned system through adding a non-polar solvent
such as n-hexane or toluene in different ratios and it was clear that
the former solvent produced better results. Finally, a mobile phase
composed of ethyl acetate:n-hexane:methanol [6:3:1, by volume]
resulted in adequate resolution between all ﬁve compounds, how-
ever, the broad and diffuse peak shapes were still unacceptable.
Gradual introduction of methylene chloride on the expense of both
ethyl acetate and n-hexane resulted in a signiﬁcant improvement
in peak shape without affecting resolution and this effect was more
pronounced by decreasing the ethyl acetate content of this quater-
nary mixture. Indeed, the total replacement of ethyl acetate with
methylene chloride while maintaining the other 2 components
provided the best and the simplest developing system in terms
of resolution, peak shape and symmetry. Finally, the developing
system was adjusted by using [methylene chloride:n-hex-
ane:methanol] in the ratio [8.8:0.3:0.9, by volume] and the spots
of ALF, TER, PRZ, DOX and FIN were observed at Rf values equiva-
lent to 0.26 ± 0.02, 0.36 ± 0.02, 0.45 ± 0.02, 0.59 ± 0.02 and
0.69 ± 0.02, respectively. The chamber was saturated with the
mobile phase at room temperature for 15 min prior to develop-
ment. The optimized procedure resulted in well-deﬁned spots with
reproducible Rf values (Fig. 2).
Pertaining to the choice of the detection wavelength, each plate
was scanned twice for the simultaneous determination of all 5
drugs in mixture. Due to the structural similarity between ALF,
TER, PRZ and DOX, they as well share similar absorption character-
istics, where they considerably absorb UV-light in the range of
247–257 nm (Fig. 3). Therefore, the universal wavelength
(254 nm) was selected for determination of the a-blockers concur-
rently. On the other hand, FIN is a steroidal compound with weak
UV absorption (Fig. 3). It exhibits considerable absorption only in
the short UV region (below 230 nm), consequently, its wavelength
of detection was optimized at 220 nm in order to enhance the sen-Fig. 3. Absorption spectra of ALF ( ), TER (sitivity of its quantiﬁcation without being affected by the high
background noise seen at lower wavelengths.
3.2. Method validation
3.2.1. Linearity and ranges
Serial dilutions of the studied drugs over the concentration
ranges stated in Table 1 were prepared in triplicates and analyzed
as previously described. The average peak areas of each drug were
plotted versus the corresponding concentrations and the calibra-
tion curve was constructed using the least squares regression
model. From the values gathered in Table 1, good linearity can be
veriﬁed from the close to unity correlation coefﬁcient
(rP 0.9994) and the low values of the relative standard deviation
of the slope (Sb% < 1.7%). The standard deviation of the residuals is
another important statistical tool to assess method linearity. In the
developed method, low values of Sy/x were obtained which desig-
nate the negligible difference between the calculated and the
found y-values and hence, the closeness of the experimental points
to the best ﬁtted regression line. Furthermore, the regression equa-
tions showed high F values which indicate steeper regression lines,
and low signiﬁcant F values which conﬁrm the less scattered
experimental points around the regression line.
3.2.2. Limits of detection and quantiﬁcation
Limits of detection (LOD) and quantiﬁcation (LOQ) were deter-
mined according the ICH recommendations [23]. LOD was calcu-
lated from 3.3S/b while LOQ was computed from 10S/b, where S
is the standard deviation of the intercept of the calibration curve,
and b is the slope. As seen from values collected in Table 1, high
method sensitivity could be inferred from the low values of LOD
that were found to be 7.85, 9.78, 4.62, 9.56 and 60.58 ng/spot for
ALF, TER, PRZ, DOX and FIN respectively.
3.2.3. Precision and accuracy
The accuracy, intra-day and inter-day precisions of the pro-
posed method were evaluated according to the ICH recommenda-
tions [23]. For each drug; method repeatability was tested through
the analysis of standard solutions prepared in triplicates at 3 con-
centration levels within the same day. On the other hand, the inter-
mediate precision was examined by analyzing standard solutions), PRZ ( ), DOX ( ) and FIN ( ).
Table 2
Precision and accuracy for the determination of ALF, DOX, PRZ, TER and FIN in bulk form using the proposed HPTLC method.
Drug Nominal value (ng/spot) Within-day Between-day
Found ± SDa (ng/spot) RSD(%)b Er(%)c Found ± SDa (ng/spot) RSD(%)b Er(%)c
ALF 80 79.49 ± 0.90 1.13 0.64 79.82 ± 1.00 1.25 0.22
200 203.73 ± 0.94 0.46 1.87 199.89 ± 3.45 1.73 0.05
300 300.82 ± 1.86 0.62 0.27 300.00 ± 5.09 1.70 0.00
TER 80 81.01 ± 1.10 1.36 1.26 78.43 ± 1.23 1.57 1.96
200 203.72 ± 1.60 0.79 1.87 197.95 ± 3.34 1.69 1.02
300 296.57 ± 2.87 0.97 1.14 300.03 ± 4.10 1.37 0.01
PRZ 50 50.14 ± 0.63 1.26 0.28 50.74 ± 0.69 1.36 1.48
100 99.29 ± 1.24 1.25 0.71 100.72 ± 1.76 1.75 0.72
150 150.96 ± 1.05 0.70 0.64 149.14 ± 1.70 1.14 0.57
DOX 80 79.98 ± 0.83 1.04 0.03 81.15 ± 1.14 1.41 1.44
200 200.28 ± 1.51 0.75 0.14 199.31 ± 2.07 1.04 0.35
300 301.67 ± 2.12 0.70 0.56 304.74 ± 2.74 0.90 1.58
FIN 500 499.91 ± 4.63 0.93 0.02 494.96 ± 9.56 1.93 1.01
1000 1012.10 ± 10.01 0.99 1.21 1002.99 ± 12.17 1.21 0.30
2000 2015.30 ± 27.88 1.38 0.77 1975.11 ± 29.40 1.49 1.24
a Mean ± standard deviation for 3 determinations.
b % Relative standard deviation.
c % Relative error.
Table 3
Determination of ALF, DOX, PRZ, TER and FIN in laboratory-prepared mixtures by the proposed HPTLC method.
Synthetic mix Drug Nominal value (ng/spot) Found ± SDa (ng/spot) RSD(%)b Er(%)c
1 ALF 200 202.72 ± 3.15 1.55 1.36
TER 200 197.76 ± 0.95 0.48 1.12
PRZ 200 196.24 ± 1.60 0.82 1.88
DOX 200 199.79 ± 3.74 1.87 0.11
FIN 200 202.36 ± 4.74 2.34 1.18
2 ALF 200 198.19 ± 1.91 0.96 0.91
TER 200 201.77 ± 2.16 1.07 0.89
PRZ 200 199.69 ± 3.55 1.78 0.16
DOX 200 200.69 ± 4.36 2.17 0.35
FIN 400 392.04 ± 4.53 1.16 1.99
3 ALF 200 199.28 ± 2.23 1.12 0.36
TER 200 198.54 ± 2.43 1.22 0.73
PRZ 100 100.26 ± 1.20 1.20 0.26
DOX 100 101.92 ± 1.23 1.21 1.92
FIN 1000 994.91 ± 17.84 1.79 0.51
4 ALF 300 300.17 ± 3.15 1.05 0.06
TER 300 302.46 ± 3.48 1.15 0.82
PRZ 60 59.68 ± 0.38 0.64 0.53
DOX 60 59.91 ± 1.15 1.92 0.15
FIN 600 605.00 ± 3.68 0.61 0.83
5 ALF 100 99.55 ± 1.67 1.68 0.45
TER 100 101.97 ± 1.98 1.94 1.97
PRZ 200 196.54 ± 4.36 2.22 1.73
DOX 200 198.14 ± 2.98 1.50 0.93
FIN 500 493.89 ± 7.49 1.52 1.22
6 ALF 100 99.17 ± 1.24 1.25 0.83
TER 200 201.48 ± 3.63 1.80 0.74
PRZ 200 203.94 ± 5.61 2.75 1.97
DOX 100 99.29 ± 1.26 1.27 0.71
FIN 500 498.23 ± 3.67 0.74 0.35
7 ALF 300 296.34 ± 3.90 1.32 1.22
TER 60 59.80 ± 0.59 0.99 0.33
PRZ 60 60.59 ± 1.23 2.03 0.98
DOX 300 300.94 ± 5.92 1.97 0.31
FIN 300 297.12 ± 5.67 1.91 0.96
a Mean ± standard deviation for ﬁve determinations.
b % Relative standard deviation.
c % Relative error.
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Table 2 compiles the obtained percentage relative standard devia-
tion (RSD%) values; which in all cases were less than 2%. Accord-
ingly such low values of RSD% can indicate the satisfactory level
of precision of the proposed method. In addition, the method can
be deemed accurate as shown by the recovered concentrations
and the values of percentage relative error (Er%) that did not exceed
±2%.3.2.4. Selectivity and speciﬁcity
The selectivity of the proposed method for the simultaneous
determination of the cited drugs was assessed through the analysis
of laboratory prepared synthetic mixtures. These were prepared in
order to contain a combination of the 5 drugs at different ratios
within their linearity ranges mentioned in Table 1. The recovered
concentration for each drug was further calculated from the corre-
sponding regression equation. As seen in Table 3, the acceptable
Fig. 4. Purity assessment of standard and tablet solutions of (a) ALF, (b) TER, (c) PRZ, (d) DOX and (e) FIN.
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deviation RSD% (62.75) and percentage relative error Er% (within
±2%) conﬁrm the accuracy, precision and selectivity of the devel-
oped method. In addition, it can be inferred that the proposed
method is adequately capable of resolving and simultaneously
quantifying the investigated drugs when present over a wide range
of ratios within solutions.
The speciﬁcity of the method was also ascertained through the
peak purity proﬁling performed by the Wincats software. Follow-
ing the recording of the UV absorption spectrum at several points
across each peak by the TLC scanner, the software is capable of
evaluating the purity of the peaks through 2 main steps. At ﬁrst,
the correlation coefﬁcient (rs,m) between the spectra extracted at
peak start and peak maximum and the correlation coefﬁcient
(re,m) between the spectra extracted at peak end and peak maxi-
mum are calculated. Secondly the software interprets mathemati-
cally the signiﬁcance of the correlation values and gives a decision
about the purity of the designated peak [24]. Following plate scan-
ning, drug spots from both standard and tablet sample solutions
were further analyzed for purity. As seen in Fig. 4, spots were
declared pure as the spectra extracted at different points across
the absorption spectra were superimposed on one another and
the calculated correlation coefﬁcients values were not less than
0.9991.
3.2.5. Robustness
Robustness of the proposed method was evaluated through
investigating its ability to remain unaffected by small but deliberatevariations in method conditions [23]. Accordingly, the wavelength
of detection was varied by a value of ±2 nm. Another parameter is
themobile phase total volume thatwas changedby±5 mL, and addi-
tionally, the individual components that were alternatively altered
by ±0.2 mL. Times of saturation and development were also varied
and their effect on quantiﬁcationwas investigated. Finally, variation
of the source of TLC plates was tested (Fluka or Merck). In all these
experiments, the variation in conditions did not have any signiﬁcant
effect on the separation or quantiﬁcation of the studied drugs. The
found percentage recoveries were between 96.96% and 102.14%. In
addition, the relative standarddeviationof peakareasdidnot exceed
3% thus conﬁrming the adequate level of method robustness
(Table 4).
3.2.6. Stability of solutions
The stability of working solutions of the ﬁve drugs in the dilut-
ing solvent (methanol) was examined and no chromatographic
changes were observed within 24 h at room temperature. Chro-
matographic parameters including Rf values and peak areas of
the drugs remained almost unchanged and no signiﬁcant degrada-
tion was observed during this period. Also, the stock solutions pre-
pared in methanol were stable for at least two weeks when kept
refrigerated at 4 C and protected from light.
4. Analysis of tablets
In order to further assess the applicability of the proposed
method, commercially available tablets containing the investigated
Table 4
Robustness of the proposed HPTLC method.
Parameter Drug Peak
area ± SD
RSD%
Detection wavelength, ±2 nm ALF 1422 ± 29 2.04
TER 1384 ± 22 1.59
PRZ 2259 ± 31 1.37
DOX 1651 ± 18 1.09
FIN 2576 ± 66 2.56
Mobile phase volume, 20 ± 5 mL ALF 1437 ± 25 1.74
TER 1409 ± 41 2.91
PRZ 2263 ± 48 2.12
DOX 1643 ± 19 1.16
FIN 2578 ± 76 2.95
Mobile phase composition (methylene
chloride:n-hexane:methanol)
(17.6 ± 0.2:0.6 ± 0.2:1.8 ± 0.2)
ALF 1446 ± 13 0.90
TER 1395 ± 35 2.51
PRZ 2250 ± 34 1.51
DOX 1616 ± 10 0.62
FIN 2597 ± 49 1.89
Time from development to scan 10, 20, 30 min ALF 1443 ± 16 1.11
TER 1369 ± 35 2.56
PRZ 2256 ± 49 2.17
DOX 1669 ± 24 1.44
FIN 2562 ± 34 1.33
Time of saturation, 15, 30, 45 min ALF 1432 ± 32 2.24
TER 1363 ± 40 2.94
PRZ 2333 ± 61 2.62
DOX 1671 ± 38 2.27
FIN 2637 ± 37 1.40
Plate source (Fluka, Merck) ALF 1455 ± 32 2.20
TER 1420 ± 7 0.49
PRZ 2313 ± 49 2.12
DOX 1640 ± 41 2.50
FIN 2695 ± 64 2.38
Table 5
Determination of ALF, DOX, PRZ, TRZ and FIN in commercial tablets by the proposed
HPTLC method.
External
standard
Reference
method
Standard
addition
ALF in Xatral
%Recovery ± SDa 100.06 ± 0.85 100.66 ± 1.01 99.06 ± 0.90
RSD% 0.85 1.00 0.91
t 1.02
F 1.42
TER in Itrin
%Recovery ± SDa 101.06 ± 1.12 100.42 ± 1.55 100.39 ± 1.21
RSD% 1.11 1.54 1.21
t 0.75
F 1.91
PRZ in Minipress
%Recovery ± SDa 99.64 ± 1.56 99.94 ± 1.22 99.60 ± 0.75
RSD% 1.57 1.22 0.75
t 0.34
F 1.64
DOX in Cardura
%Recovery ± SDa 100.08 ± 0.94 100.74 ± 1.43 100.06 ± 1.00
RSD% 0.94 1.42 1.00
t 0.86
F 2.31
FIN in Proscar
%Recovery ± SDa 99.40 ± 0.87 100.22 ± 0.87 99.78 ± 1.14
RSD% 0.88 0.87 1.14
t 1.48
F 1.01
a Mean ± standard deviation for ﬁve determinations. Theoretical values for t and F
are 2.31 and 6.39, respectively.
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precise, accurate and in good agreement with the label claim as dis-
played by the adequate values of percentage recoveries, standarddeviation and RSD(%) (Table 5). HPLC-UV reference methods were
also applied for the quantiﬁcation of TER, PRZ and DOX [16] as well
as the determination of ALF [7] and FIN [25]. Results obtained from
the proposed method as well as the reference ones were statisti-
cally comparedwith one another using the Student’s t-test for accu-
racy and the variance ratio F-test for precision. Calculated t and F
values were less than the tabulated ones for each drug representing
the insigniﬁcant difference between the reported and the proposed
method at the 95% conﬁdence level. The standard addition tech-
nique was also applied by spiking tablet sample solutions with
known volumes of the corresponding standard solution to obtain
total concentrations within the speciﬁed concentration ranges
and the recovery of each drug was then calculated. The good recov-
eries obtained using both external standard and standard addition
methods suggest that there was no interference from the co-formu-
lated inactive ingredients (Table 5). It can be concluded that the sat-
isfactory analytical performance of the method fortiﬁes its aptness
for the routine analysis of any of the selected drugs in quality con-
trol units.5. Conclusion
To the best of our knowledge, the literature contains no records
of a generic method that allows the simultaneous determination of
alfuzosin, doxazosin, prazosin, terazosin and ﬁnasteride by any
analytical methodology. HPTLC exhibits several advantages over
HPLC and consequently it is sometimes favored over it. HPTLC con-
sumes by far less amount of solvents and therefore can be regarded
as more economic and environment friendly. In addition, it is a fast
method of analysis allowing the simultaneous processing of large
number of samples with no memory effect. Furthermore, it allows
the detection of all compounds even those strongly retained on
baseline. Indeed, HPTLC does not require elaborate treatment or
the sophisticated experimental setup usually associated with HPLC
methods of analysis. This work describes a simple, sensitive and
robust HPTLC method for the simultaneous determination of the
aforementioned drugs in their bulk form. The proposed method
met the ICH validation acceptance criteria concerning; linearity,
ranges, precision and accuracy. The selectivity of the proposed
method was evaluated through the analysis of several laboratory
prepared mixtures at different ratios within the linearity ranges
of the drugs. In addition, the applicability of the proposed method
to real life situations was assessed through the analysis of com-
mercially available tablets and satisfactory results were obtained
in comparison to other reported methods.Conﬂicts of interest
The authors declared no conﬂicts of interest.References
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